GNE Myopathy Phenotypes and Therapeutic Approaches

GNE myopathy is an ultra-rare, adult-onset muscle disorder caused by bi-allelic mutations in the GNE gene, which encodes a bifunctional enzyme responsible for the first two steps of sialic acid biosynthesis. Clinically, the disease is characterised by a distal muscle weakness that often spares the quadriceps and progresses to significant disability over 10–20 years. Pathologically, affected muscles exhibit rimmed vacuoles and fibre atrophy linked to insufficient sialylation of key glycoproteins and glycolipids. Phenotypic variability is influenced by genotype, post-translational modifications and environmental factors. Therapeutic approaches under investigation include oral supplementation of sialic acid or its precursors (such as N-acetylmannosamine and aceneuramic acid), gene replacement strategies, small-molecule modulators of GNE activity and targeted delivery systems. Concurrent efforts to identify minimally invasive biomarkers—ranging from lipidomic signatures to circulating glycan profiles—promise to accelerate diagnosis, stratify patients by severity and monitor response to therapy. Together, these advances are forging a translational pathway from molecular insight to patient-centred interventions.

Research from Nature Portfolio

A high-resolution structural study of the human GNE epimerase domain has revealed the tetrameric assembly and the binding mode of UDP-GlcNAc and the feedback inhibitor CMP-Neu5Ac. The work elucidates mechanistic differences between hydrolysing and non-hydrolysing epimerases, highlights key residues governing substrate turnover and identifies an intersubunit interface as a novel allosteric site. By mapping disease-associated mutations onto this framework, the study provides a rational basis for the design of small-molecule modulators aimed at restoring enzyme function and sialic acid flux in patient muscle cells.

GNE Myopathy Phenotypes and Therapeutic Approaches publication trend

The graph below shows the total number of articles in gne myopathy phenotypes and therapeutic approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Bifunctional GNE enzyme: A single polypeptide harbouring UDP-GlcNAc 2-epimerase and ManNAc kinase activities, essential for sialic acid biosynthesis.

Hyposialylation: A deficiency in sialic acid incorporation into glycoproteins or glycolipids, impairing muscle membrane stability and function.

Aceneuramic acid: A form of sialic acid administered orally or in extended-release formulations to replenish deficient glycan end-products.

Lipidomics: The systematic analysis of lipid species in biological samples to identify disease-associated metabolic alterations.

Post-translational glycation: Non-enzymatic addition of sugar-derived carbonyls to proteins, potentially reducing enzyme activity and accelerating disease onset.

References

1. GNE myopathy: from clinics and genetics to pathology and research strategies. Orphanet Journal of Rare Diseases (2018).
2. Mechanism and inhibition of human UDP-GlcNAc 2-epimerase, the key enzyme in sialic acid biosynthesis. Scientific Reports (2016).
3. Ion Mobility QTOF-MS Untargeted Lipidomics of Human Serum Reveals a Metabolic Fingerprint for GNE Myopathy. Molecules (2024).
4. Glycation Interferes with the Activity of the Bi-Functional UDP-N-Acetylglucosamine 2-Epimerase/N-Acetyl-mannosamine Kinase (GNE). Biomolecules (2023).
5. Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. Genetics in Medicine (2021).
6. Reduction of UDP-N-acetylglucosamine 2-Epimerase/N-Acetylmannosamine Kinase Activity and Sialylation in Distal Myopathy with Rimmed Vacuoles*. Journal of Biological Chemistry (2004).